EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 9th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations • New Jersey
Contract Type FiledOctober 9th, 2024 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 7th day of October, 2024, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Chris Degnan (the “Executive”) (collectively, the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 21st, 2022 • UroGen Pharma Ltd. • Pharmaceutical preparations • New Jersey
Contract Type FiledMarch 21st, 2022 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 20th day of March, 2022 (the “Effective Date”), between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Dong Kim (the “Executive”) (collectively, the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 9th, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations • New Jersey
Contract Type FiledNovember 9th, 2020 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 12th day of August, 2020, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Jason Smith (the “Executive”) (collectively, the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 9th, 2020 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 9th, 2020 Company Industry JurisdictionThis Executive Employment Agreement (the “Agreement”), is hereby made this 3rd day of September, 2020, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the “Parent”, and the Subsidiary and the Parent together, the “Company”), and Molly Henderson (the “Executive”) (collectively, the “Parties”).